BridgeMD
New treatment option for Obscure Gastrointestinal Bleeding
Official title Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
ClinicalTrials.gov ID: NCT07089030
What this study is testing
- What it's testing
- This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Adult men and postmenopausal women with iron deficiency anemia, and premenopausal women with iron deficiency anemia and a negative gynecological...
- Patients receiving anticoagulant or antiplatelet therapy
- Negative esophagogastroduodenoscopy (EGD), colonoscopy, and capsule endoscopy for gastrointestinal bleeding within six months prior to study...
- Willing and able to provide written informed consent
- Able to read and understand French
You likely can't join if
- Ongoing overt gastrointestinal bleeding
- Acute coronary syndrome, acute neurological event, sepsis, or respiratory failure within the past week
- Pregnant women
- Known gastrointestinal or hematological malignancy
- Contraindications to capsule endoscopy
- History of bariatric surgery, gastrectomy, or segmental resection of the small intestine
See the full eligibility criteria
- Adult men and postmenopausal women with iron deficiency anemia, and premenopausal women with iron deficiency anemia and a negative gynecological evaluation; a. Laboratory-confirmed iron deficiency anemia (hemoglobin \<...
- Patients receiving anticoagulant or antiplatelet therapy
- Negative esophagogastroduodenoscopy (EGD), colonoscopy, and capsule endoscopy for gastrointestinal bleeding within six months prior to study enrollment
- Willing and able to provide written informed consent
- Able to read and understand French
- Ongoing overt gastrointestinal bleeding
- Acute coronary syndrome, acute neurological event, sepsis, or respiratory failure within the past week
- Pregnant women
- Known gastrointestinal or hematological malignancy
- Contraindications to capsule endoscopy
- History of bariatric surgery, gastrectomy, or segmental resection of the small intestine
- Inability to take oral iron
- Other sources of blood loss (e.g., urinary, gynecological, hematoma, hemolysis)
The study team makes the final eligibility decision.
Where it's taking place
- Trois-Rivières, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Trois-Rivières, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.